Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study)Giovanni Martinotti, Massimo di Giannantonio, Alessandro Bertolino et al.|Journal of Affective Disorders|2022Cited by 130
Evidence of an interaction between <i>FXR1</i> and <i>GSK3β</i> polymorphisms on levels of Negative Symptoms of Schizophrenia and their response to antipsychoticsAntonio Rampino, Giuseppe Blasi, Silvia Torretta et al.|European Psychiatry|2021Cited by 8